HOME
>
臨床医学：内科
>
血液
> ここまできた白血病/MDS治療

ここまできた白血病/MDS治療

出版社：	中山書店
著者：	金倉譲(総編集) 松村到(専門編集)
発行日：	2013-10-25
分野：	臨床医学：内科 > 血液
ISBN：	9784521737775
電子書籍版：	2013-10-25 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

11,000 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

11,000 円(税込)

購入する

商品紹介

白血病/MDS診療は，革新的な分子生物学的解析手法によって，大きな変容を遂げている．本書では，この最新の知見に基づいて，疾患概念や分類，検査などのほか，薬物や放射線，造血幹細胞移植などの完治をめざす治療法や支持療法について解説する．また，治療各論として，白血病/MDSのタイプごとに，臨床試験の結果を踏まえた最適な治療法を詳述し，書名にある“ここまできた”が実感できる内容にまとめている．

目次

ここまできた白血病/MDS治療

―目次―

第1章　総論
第2章　分類
第3章　検査・診断
第4章　治療総論
第5章　治療各論
第6章　支持療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章総論

P.7 掲載の参考文献

1) Brunning RD, et al. Myelodysplastic syndromes/neoplasms, overview. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC press ; 2008. pp.88-93.

2) Wimazal F, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS : the diagnostic interface. Leuk Res 2007 ; 31 : 1461-7.

3) Vardiman JW, et al. Introduction and overview of the classification of the myeloid neoplasms. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC press ; 2008. pp.18-30.

4) Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012 ; 120 : 2454-65.

P.11 掲載の参考文献

1) Curado MP, et al. eds. Cancer Incidence in Five Continents, Vol IX. IARC Scientific Publication, No 160. Lyon : IARC press ; 2009.

2) Matsuda A, et al. Cancer incidence and incidence rates in Japan in 2007 : a study of 21 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2013 ; 43 : 328-36. (国立がん研究センターがん対策情報センター : http://ganjoho.jp/professional/statistics/statistics.html#02)

3) 厚生労働省大臣官房統計情報部, 編. 人口動態統計. 人口動態統計によるがん死亡データ. 1958年～2011年.

4) Surveillance, Epidemiology and End Results (SEER) Program. http://seer.cancer.gov/

5) 日本血液学会統計・調査委員会, 編. 日本血液学会2010年次血液疾患症例登録集計解析結果. http://www.jshem.or.jp/member/pdf/2010-result.pdf

6) 日本血液学会統計・調査委員会, 編. 日本血液学会2011年次血液疾患症例登録集計解析結果, 改定版 Ver.1.1. http://www.jshem.or.jp/member/pdf/2011-result11.pdf

P.15 掲載の参考文献

1) Valent P, et al. Cancer stem cell definitions and terminology : the devil is in the details. Nat Rev Cancer 2012 ; 12 : 767-75.

2) Lapidot T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994 ; 367 : 645-8.

3) Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997 ; 3 : 730-7.

4) Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005 ; 5 : 311-21.

5) Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. Haematologica 2012 ; 97 : 966-74.

6) Goardon N, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011 ; 19 : 138-52.

7) Felipe Rico J, et al. Acute myelogenous leukemia stem cells : From Bench to Bedside. Cancer Lett 2012.

8) Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012 ; 150 : 264-78.

9) Kikushige Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010 ; 7 : 708-17.

10) Matsunaga T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003 ; 9 : 1158-65.

P.26 掲載の参考文献

1) Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012 ; 150 : 264-78.

2) Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC press ; 2008.

3) Murati A, et al. Myeloid malignancies : mutations, models and management. BMC Cancer 2012 ; 12 : 304.

4) Shih AH, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012 ; 12 : 599-612.

5) Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 ; 478 : 64-9.

6) Grimwade D, et al. Refinement of cytogenetic classification in acute myeloid leukemia : determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010 ; 116 : 354-65.

7) Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 ; 89 : 2079-88.

8) Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012 ; 120 : 2454-65.

9) Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012 ; 366 : 1079-89.

10) Moran-Crusio K, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011 ; 20 : 11-24.

11) Bejar R, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012 ; 30 : 3376-82.

第2章分類

P.38 掲載の参考文献

1) Bennett JM, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976 ; 33 : 451-8.

2) Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 ; 51 : 189-99.

3) Jaffe ES, et al., eds. WHO Classificatio of Tumours : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC press ; 2001.

4) Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC press ; 2008.

第3章検査・診断

P.53 掲載の参考文献

1) Bennett JM, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976 ; 33 : 451-8.

2) Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC press ; 2008.

3) Goasguen JE, et al. Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome. Leuk Res 1991 ; 15 : 1159-65.

4) Mufti GJ, et al. Diagnosis and classification of myelodysplastic syndrome : International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008 ; 93 : 1712-7.

5) Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 ; 51 : 189-99.

6) 朝長万左男, 松田晃, 編. 不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究. 2008.

7) Germing U, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Dusseldorf Registry on myelodysplastic syndromes. Leuk Res 2012 ; 36 ; 727-34.

P.56 掲載の参考文献

東克巳. 特殊染色. 金井正光, 監修. 臨床検査法提要. 改訂第33版. 東京 : 金原出版 ; 2010. pp.218 -25.

P.62 掲載の参考文献

米山彰子. 表面形質. 浅野茂隆ほか, 監修. 三輪血液病学. 第3版. 東京 : 文光堂 ; 2006. pp. 567-80.

米山彰子. フローサイトメトリー. 浅野茂隆ほか, 監修. 三輪血液病学. 第3版. 東京 : 文光堂 ; 2006. pp. 1945-54.

米山彰子. フローサイトメトリー解析. 東原正明ほか, 編. 血液内科クリニカルスタンダード. 第2版. 東京 : 文光堂 ; 2008. pp. 49-52.

米山彰子. 細胞表面抗原. 日本サイトメトリー技術者認定協議会, 編. スタンダードフローサイトメトリー. 東京 : 医歯薬出版 ; 2009. pp. 55-79.

P.66 掲載の参考文献

1) 谷脇雅史, 編著. 血液腫瘍-MIC-M診断から治療まで. 東京 : 先端医学社 ; 2005.

2) 阿部達生, 編著. 造血器腫瘍アトラス-形態, 免疫, 染色体と遺伝子, 改訂第3版. 東京 : 日本医事新報社 ; 2000.

3) Shaffer LG, et al., eds. ISCN (2005) : An International System for Human Cytogenetic Nomenclature. Basel : S. Karger ; 2005.

4) Schrock E, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996 ; 273 : 494-7.

5) Nagoshi H, et al. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res 2012 ; 72 : 4954-62.

6) Lee C, et al. Limitations of chromosome classification by multicolor karyotyping. Am J Hum Genet 2001 ; 68 : 1043-7.

7) Chinen Y, et al. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t (2 ; 21) (q11 ; q22) by bubble PCR method for cDNA. Oncogene 2008 ; 27 : 2249-56.

8) Kobayashi S, et al. Identification of IGHC δ-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia. Genes Chromosomes Cancer 2011 ; 50 : 207-16.

P.69 掲載の参考文献

1) 谷脇雅史, 編著. 血液腫瘍-MIC-M診断から治療まで. 東京 : 先端医学社 ; 2005.

2) Akasaka T, et al. Nonimmunoglobulin (non-Ig) /BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6. Blood 2000 ; 96 : 2907-9.

3) Li H, et al. A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 2008 ; 321 : 1357-61.

4) Limpens J, et al. Lymphoma-associated translocation t (14 ; 18) in blood B cells of normal individuals. Blood 1995 ; 85 : 2528-36.

5) Miyamoto T, et al. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8 ; 21 chromosomal translocation. Proc Natl Acad Sci U S A 2000 ; 97 : 7521-6.

6) Gingeras TR. Implications of chimaeric non-co-linear transcripts. Nature 2009 ; 461 : 206-11.

P.75 掲載の参考文献

1) Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC press ; 2008.

2) Dohner H, et al. Diagnosis and management of acute myeloid leukemia in adults : recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010 ; 115 : 453-74.

3) Schlenk RF, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008 ; 358 : 1909-18.

4) Baccarani M, et al. Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009 ; 27 : 6041-51.

第4章治療総論

P.84 掲載の参考文献

1) Brunton LL, ed. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill Medical ; 2010.

2) 日本癌治療学会, 編. 制吐薬適正使用ガイドライン, 2010年5月. 東京 : 金原出版 ; 2010.

3) 聖路加看護大学外来がん化学療法看護ワーキンググループ, 編. 外来がん化学療法看護ガイドライン-抗がん剤の血管外漏出の予防・早期発見・対処, 2009年版. 東京 : 金原出版 ; 2009.

American Society of Clinical Oncology, Kris MG, et al. American Society of Clinical Oncology guideline for antiemetics in oncology : update 2006. J Clin Oncol 2006 ; 24 : 2932-47.

Ener RA, et al. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004 ; 15 : 858-62.

P.93 掲載の参考文献

1) 分子標的薬-がんから他疾患までの治癒をめざして. 日本臨牀 2012, 70 増刊号.

2) Johnson LN. Protein kinase inhibitors : contributions from structure to clinical compounds. Q Rev Biophys 2009 ; 42 : 1-40.

3) Kelly KR, et al. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol 2011 ; 6 : 53-61.

4) Frankland-Searby S, Bhaumik SR. The 26S proteasome complex : an attractive target for cancer therapy. Biochim Biophys Acta 2012 ; 1825 : 64-76.

5) Ververis K, et al. Histone deacetylase inhibitors (HDACIs) : multitargeted anticancer agents. Biologics 2013 ; 7 : 47-60.

6) Ungewickell A, Medeiros BC. Novel agents in acute myeloid leukemia. Int J Hematol 2012 : 96 : 178-85.

7) Kollareddy M, et al. Aurora kinase inhibitors : progress towards the clinic. Invest New drugs 2012 ; 30 : 2411-32.

Wodicka LM, et al. Activation state-dependent binding of small molecule kinase inhibitors : structural insights from biochemistry. Chem Biol 2010 ; 17 : 1241- 9.

P.98 掲載の参考文献

1) 山崎岐男. 孤高の科学者W. C. レントゲン. 東京 : 医療科学社 ; 1995. pp.134-7.

2) 日本放射線腫瘍学会, 編. 日本放射線腫瘍学会25周年記念誌. 2012.

3) Roberts KB, et al. Total-body and hemibody irradiation. In : Halperin EC, et al., eds. Perez and Brady's Principles and Practice of Radiation Oncology. 5th ed. Philadelphia : Lippincott Williams & Wilkins ; 2007. pp.364-77.

4) 副島俊典. 全身照射. 大西洋ほか, 編. がん・放射線療法 2010. 東京 : 篠原出版新社 ; 2010. pp.514-20.

5) Cosset JM, et al. Single dose versus fractionnated total body irradiation before bone marrow transplantation : radiobiological and clnical considerations. Int J Radiat Oncol Biol Phys 1994 ; 30 : 477-92.

6) Oya N, et al. Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation : acute parotitis may predict interstitial pneumonitis. Int J Hematol 2006 ; 83 : 86-91.

7) Izawa H, et al. Effect of dose fractionation on pulmonary complications during total body irradiation. J Radiat Res 2011 ; 52 : 502-8.

8) Hartman AR, et al. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation : a meta-analysis. Bone Marrow Transplantation 1998 ; 22 : 439-43.

9) Roberts KB, Seropian S. Leukemia. In : Halperin EC, et al., eds. Perez and Brady's Principles and Practice of Radiation Oncology. Philadelphia : Lippincott Williams & Wilkins ; 2007. pp.1777-89.

10) Weinmann M, et al. Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disorders. Radiother Oncol 2001 ; 58 : 235-46.

P.105 掲載の参考文献

1) Kanda Y, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003 ; 102 : 1541-7.

2) Kanda J, et al. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation : a nationwide retrospective study. Blood 2012 ; 119 : 2409-16.

3) Kanda J, et al. Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. Leukemia 2013 ; 27 : 286-94.

4) M orishima Y, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002 ; 99 : 4200-6.

5) Sasazuki T, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998 ; 339 : 1177-85.

6) Kawase T, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007 ; 110 : 2235-41.

7) Kanda Y, et al. Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation. Br J Haematol 2013 ; 161 : 566-77.

8) 森毅彦, 岡本真一郎. 各種造血幹細胞移植の利点と欠点-海外バンクドナーからの移植. 臨床血液 2002 ; 43 : 438-41.

9) Takanashi M, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010 ; 116 : 2839-46.

10) Yoshihara S, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012 ; 47 : 508-15.

11) Atsuta Y, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009 ; 113 : 1631-8.

12) Ichinohe T, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA) -mismatched family members linked with long-term fetomaternal microchimerism. Blood 2004 ; 104 : 3821-8.

13) Ogawa H, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008 ; 36 : 1-8.

14) Ogawa H, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006 ; 12 : 1073-84.

15) Kanda Y, et al. In vivo alemtuzumab enables haploidentical human leukocyte antigenmismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005 ; 79 : 1351-7.

P.111 掲載の参考文献

1) Doroshow J. Pharmacological basis for high-dose chemotherapy. In : Thomas ED, et al., eds. Hematopoietic Cell Transplantation. Malden MA : Blackwell Science ; 1999. pp.103-17.

2) Hartman AR, et al. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation : a meta-analysis. Bone Marrow Transplant 1998 ; 22 : 439-43.

3) Sanders JE. Growth and development after hematopoietic cell transplantation. In : Blume KG, et al., eds. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Malden, MA : Blackwell Publishing ; 2004. pp.929-43.

4) Kanda Y, et al. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant 2005 ; 11 : 881-9.

5) Mohty M, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia : a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010 ; 116 : 4439-43.

6) Bornhauser M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission : a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012 ; 13 : 1035-44.

P.120 掲載の参考文献

1) Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease : I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005 ; 11 : 945-56.

2) Dignan FL, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012 ; 158 : 30-45.

3) Dignan FL, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012 ; 158 : 46-61.

4) Ruutu T, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT : a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012 ; 47 : 1459-64.

5) Gooley TA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010 ; 363 : 2091-101.

6) Alousi AM, et al. Graft-versus-host disease : state of the science. Biol Blood Marrow Transplant 2013 ; 19 (1 Suppl) : S102-8.

7) Jacobsohn DA. Optimal management of chronic graft-versus-host disease in children. Br J Haematol 2010 ; 150 : 278-92.

8) Kawase T, et al. HLA mismatch combinations associated with decreased risk of relapse : implications for the molecular mechanism. Blood 2009 ; 113 : 2851-8.

9) Ringden O, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009 ; 113 : 3110-8.

10) Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol 2011 ; 29 : 1855-63.

11) Kanda Y, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia 2004 ; 18 : 1013-9.

12) Inamoto Y, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood 2011 ; 118 : 456-63.

P.129 掲載の参考文献

1) Gratwohl A, et al ; Acute and Chronic Leukemia Working Parties ; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias : an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005 ; 36 : 757-69.

2) Tomblyn M, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients : a global perspective. Biol Blood Marrow Transplant 2009 ; 15 : 1143-238.

3) Nakamae H, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009 ; 15 : 694-703.

4) Portugal RD, et al. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 2009 ; 27 : 3849-54.

5) Coppell JA, et al. Hepatic veno-occlusive disease following stem cell transplantation : incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010 ; 16 : 157-68.

6) Lee JH, et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002 ; 118 : 1087-94.

7) Kataoka K, et al. Plasma brain natriuretic peptide is associated with hepatic venoocclusive disease and early mortality after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010 ; 45 : 1631-7.

8) Heikinheimo M, et al. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994 ; 83 : 3036-40.

9) Park YD, et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 1997 ; 19 : 915-20.

10) Fried MW, et al. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 2001 ; 27 : 635-9.

11) Nicolau C, et al. Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver. J Ultrasound Med 1993 ; 12 : 437-40.

12) Lassau N, et al. Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease. Transplantation 2002 ; 74 : 60-6.

13) Carreras E, et al. Hepatic veno-occlusive disease after bone marrow transplant. Blood Rev 1993 ; 7 : 43-51.

14) McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010 ; 51 : 1450-60.

15) 平林紀男. TMAによる虚血性腸炎の生検診断. 血液・腫瘍科 2000 ; 41 : 428-37.

Cordonnier C, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients : a randomized, controlled trial. Clin Infect Dis 2009 ; 48 : 1042-51.

第5章治療各論

P.138 掲載の参考文献

1) Ohtake S, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia : the JALSG AML201 Study. Blood 2011 ; 117 : 2358-65.

2) Miyawaki S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML201 Study. Blood 2011 ; 117 : 2366-72.

3) Fernandez HF, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009 ; 361 : 1249-59.

4) Bishop JF, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990 ; 75 : 27-32.

5) Bishop JF, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996 ; 87 : 1710-7.

6) Weick JK, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia : a Southwest Oncology Group study. Blood 1996 ; 88 : 2841-51.

7) Castaigne S, et al ; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701) : a randomised, open-label, phase 3 study. Lancet 2012 ; 379 : 1508-16.

P.144 掲載の参考文献

1) Dohner H, et al. Diagnosis and management of acute myeloid leukemia in adults : recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010 ; 115 : 453-74.

2) Grimwade D, et al. Refinement of cytogenetic classification in acute myeloid leukemia : determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010 ; 116 : 354-65.

3) Kuriyama K, et al. [Scoring systems for predicting prognoses of the patients with AML treated according to the Japan Adult Leukemia Study Group (JALSG) protocols]. Rinsho Ketsueki 1998 ; 39 : 98-102.

4) Metzeler KH, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia : a Cancer and Leukemia Group B study. J Clin Oncol 2011 ; 29 : 1373-81.

5) Miyawaki S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML201 Study. Blood 2011 ; 117 : 2366-72.

6) Sakamaki H, et al. Allogeneic stem cell transplantation versus chemotherapy as postremission therapy for intermediate or poor risk adult acute myeloid leukemia : results of the JALSG AML97 study. Int J Hematol 2010 ; 91 : 284-92.

7) Koreth J, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission : systematic review and meta-analysis of prospective clinical trials. JAMA 2009 ; 301 : 2349-61.

8) Schlenk RF, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008 ; 358 : 1909-18.

P.156 掲載の参考文献

1) Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse : a comprehensive review of the literature. Leuk Lymphoma 2002 ; 43 : 1715-27.

2) Kurosawa S, et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 2010 ; 95 : 1857-64.

3) Miyawaki S, et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma 2010 ; 51 : 1855-61.

4) Armistead PM, et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 2009 ; 15 : 1431-8.

5) Breems DA, et al. Prognostic index for adult acute myeloid leukemia in first relapse. J Clin Oncol 2005 ; 23 : 1969-78.

6) Larson RA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005 ; 104 : 1442-52.

7) Ho AD, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. J Clin Oncol 1988 ; 6 : 213-7.

8) Amadori S, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine : an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991 ; 9 : 1210-4.

9) 宮脇修一, ほか. 再発急性骨髄性白血病に対するmitoxantrone・etoposide・cytarabine併用 (MEC) 療法. Int J Hematol 1995 ; 61 (suppl 1) : 99.

10) Archimbaud E, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991 ; 77 : 1894-900.

11) Hiddemann W, et al. High-dose cytosine arabinoside and mitoxantrone : preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias. Onkologie 1988 ; 11 : 10-2.

12) Yamada K, et al. Concurrent use of granulocyte colony-stimulating factor with lowdose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia : a pilot study. Leukemia 1995 ; 9 : 10-4.

13) Miyawaki S, et al. Phase 2 Study of FLAGM (Fludarabine+High-dose ara-C+G-CSF+Mitoxantrone) for refractory or relapse acute myeloid leukemia (AML) : a Report from the Japan Adult Leukemia Study Group (JALSG). Blood 2009 ; 114 : 437. Abstract 1058.

14) 日本造血細胞移植学会. 平成23年度全国調査報告書. 2012. p.96.

15) Biggs JC, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992 ; 80 : 1090-3.

16) Schmid C, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006 ; 108 : 1092-9.

Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012 : 43-8.

P.163 掲載の参考文献

1) Sanz MA, et al. Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009 ; 113 : 1875-91.

2) Asou N, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy : the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007 ; 110 : 59-66.

3) Avvisati G, et al. Induction therapy with idarubicin alone significantly influences eventfree survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia : final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002 ; 100 : 3141-6.

4) Sanz MA, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR α-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999 ; 94 : 3015-21.

5) Fenaux P, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999 ; 94 : 1192-200.

6) Tallman MS, et al. All-trans retinoic acid in acute promyelocytic leukemia : long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002 ; 100 : 4298-302.

7) Shinagawa K, et al ; A Phase III Study of New Synthetic Retinoid Tamibarotene (Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL). Japan Adult Leukemia Study Group (JALSG) APL204 Study. Blood 2012 ; 120 : abst. #410.

8) Lo-Coco F, et al ; ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL). Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. Blood 2012 ; 120 : abst. #410.

9) Ono T, et al. Clinical features and outcomes of elderly patients with acute promyelocytic leukemia (APL) -The Japan Adult Leukemia Study Group APL97 Study. Cancer Sci 2012 ; 103 : 1974-8.

10) Sanz MA, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004 ; 104 : 3490-3.

P.170 掲載の参考文献

1) Niu C, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide : remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999 ; 94 : 3315-24.

2) Shigeno K, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia : updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005 ; 82 : 224-9.

3) Yanada M, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. The JALSG APL205R Study. Blood 2013 ; 121 : 3095-102.

4) Takeshita A, et al. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. Ann Intern Med 1996 ; 124 : 893-6.

5) Tobita T, et al. Treatment with a new synthetic retinoid, Am-80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997 ; 90 : 967-73.

6) Shinjo K, et al. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid. Int J Hematol 2000 ; 72 : 470-3.

7) Lo-Coco F, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia Blood 2004 ; 104 : 1995-9.

8) Takeshita A, et al. Efficacy of gemtuzumab ozogamicin (GO) on relapsed/refractory acute promyelocytic leukemia (APL). Blood 2011 ; 118 : #1532, 667-8.

9) Mandelli F, et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant 1994 ; 14 : 293-8.

10) Sanz MA, et al. Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era : a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007 ; 39 : 461-9.

P.175 掲載の参考文献

1) Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol 2009 ; 132 : 410-25.

2) Vardiman JW, et al. Therapy-related myeloid neoplasms. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC press ; 2008. pp.127-9.

3) Smith SM, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia : the University of Chicago series. Blood 2003 ; 102 : 43-52.

4) Schoch C, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML) : an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004 ; 18 : 120-5.

5) Andersen MK, et al. Balanced chromosome abnormalities inv (16) and t (15 ; 17) in therapy-related myelodysplastic syndromes and acute leukemia : report from an international workshop. Genes Chromosomes Cancer 2002 ; 33 : 395-400.

6) Dayyani F, et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 2011 ; 117 : 110-5.

7) Litzow MR, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010 ; 115 : 1850-7.

8) Kwong YL. Azathioprine : association with therapy-related myelodysplastic syndrome and acute myeloid leukemia. J Rheumatol 2010 ; 37 : 485-90.

9) Kern W, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004 ; 22 : 2510-1.

10) Kayser S, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011 ; 117 : 2137-45.

Gruschkus SK , et al. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer 2010 ; 116 : 5279-89.

P.178 掲載の参考文献

1) Borowitz MJ, et al. Acute leukaemias of ambiguous lineage. In : Swerdlow SH, et al., eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon ; IARC press : 2008. pp.150-5.

2) Towatari M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004 ; 104 : 3507-12.

3) Wang Y, et al. Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult. Int J Hematol 2011 ; 94 : 552-5.

4) Bene MC, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995 ; 9 : 1783-6.

5) Al-Seraihy AS, et al. Clinical characteristics and outcome of children with biphenotypic acute leukemia. Haematologica 2009 ; 94 : 1682-90.

6) Yan L, et al. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica 2012 ; 97 : 1708-12.

7) Matutes E, et al. Mixed-phenotype acute leukemia : clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 2011 ; 117 : 3163-71.

P.185 掲載の参考文献

1) Jinnai I, et al. Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia : the JALSG-ALL97 study. Int J Hematol 2010 ; 92 : 490-502.

2) Kantarjian HM, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000 ; 18 : 547-61.

3) 小川千登世. L-asparaginase治療の問題点と対策. 日本小児血液学会雑誌 2010 ; 24 : 14-24.

4) Stock W. Outcome of adolescents and young adults with ALL : A comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens. ASH Annual Meeting Abstracts 2000.

5) Ribera JM, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008 ; 26 : 1843-9.

6) Sakura T, et al. Outcome of Pediatric-Type Therapy for Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) : A Study by the Japan Adult Leukemia Study Group (JALSG ALL202-U study). ASH Annual Meeting Abstracts 2012 ; 120 : 1464.

7) 直江知樹, 編. 現場で役立つ血液腫瘍治療プロトコール集. 改訂版. 大阪 : 医薬ジャーナル社 ; 2011.

P.192 掲載の参考文献

1) Takeuchi J, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia 2002 ; 16 : 1259-66.

2) Sakura T, et al. Outcome of Pediatric-Type Therapy for Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) : A Study by the Japan Adult Leukemia Study Group (JALSG ALL202-U study). ASH Annual Meeting Abstracts 2012 ; 120 : 1464.

3) 日本造血細胞移植学会ガイドライン委員会. 造血幹細胞移植の適応ガイドライン. 2002.

4) Thomas X, et al. Outcome of treatment in adults with acute lymphoblastic leukemia : analysis of the LALA-94 trial. J Clin Oncol 2004 ; 22 : 4075-86.

5) 日本造血細胞移植学会. 平成21年度全国調査報告書. 2010.

6) Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies : an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005 ; 23 : 5074-87.

P.201 掲載の参考文献

1) Koller CA, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997 ; 11 : 2039-44.

2) Esterhay RJ, et al. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia. Blood 1982 ; 59 : 334-45.

3) Hiddemann W, et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 1990 ; 4 : 637-40.

4) Thomas DA, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006 ; 106 : 1569-80.

5) DeAngelo DJ, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma : Cancer and Leukemia Group B study 19801. Blood 2007 ; 109 : 5136-42.

6) Gokbuget N, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011 ; 118 : 3504-11.

7) 日本造血細胞移植学会. 平成23年度全国調査報告書. 名古屋 : 日本造血細胞移植学会データセンター ; 2012.

8) Gokbuget N, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012 ; 120 : 2032-41.

9) O'Brien S, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008 ; 113 : 3186-91.

10) Topp MS, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012 ; 120 : 5185-7.

11) Kalos M, et al. Sustained functional T cell persistence and B cell aplasia following CD19-targeting adoptive T cell immunotherapy for relapsed, refractory CD19+ malignancy. Blood 2012 ; 120 : Abstract 756.

P.209 掲載の参考文献

1) Burmeister T, et al. Patients' age and BCR-ABK frequency in adult B-precoursor ALL : a retrospective analysis from the GMALL study group. Blood 2008 ; 112 : 918-9.

2) Fielding AK, et al. Prospective ontcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lmphoblastic leukemia confirms superiority of allogeneic transplant over chemotherapy in the pre-imatinib era : results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009 ; 113 : 4489-96.

3) Boulos N, et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood 2011 ; 117 : 3585-95.

4) Mizuta S, et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011 ; 25 : 41-7.

5) Yanada M, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006 ; 24 : 460-6.

6) Kano Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001 ; 97 : 1999-2007.

7) Fielding AK, et al, Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia ; final results of the UKALLXII/ECOG2993 trial. ASH2010. #169.

8) Vignetti M, et al. imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy : results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007 ; 109 : 3676-8.

9) Rives S, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL) : results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011 ; 154 : 600-11.

10) Schultz KR, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia : a children's oncology group study. J Clin Oncol 2009 ; 27 : 5175-81.

11) Biondi A, et al. imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL) : a randomised, open-label, intergroup study. Lancet Oncol 2012 ; 13 : 936-45.

12) Ravandi F, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010 ; 116 : 2070-7.

13) Foa R, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011 ; 118 : 6521-8.

14) Cortes JE, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012 ; 367 : 2075-88.

15) Carpenter PA, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007 ; 109 : 2791-3.

16) Wassmann B, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2005 ; 106 : 458-63.

P.216 掲載の参考文献

1) Rees JK, et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986 ; 2 : 1236-41.

2) Appelbaum FR, et al. Age and acute myeloid leukemia. Blood 2006 ; 107 : 3481-5.

3) Schaich M. Elderly acute myeloid leukemia : patients are not all the same. Haematologica 2004 ; 89 : 261-3.

4) Weick JK, et al. A Randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia : A Southwest Oncology Group study. Blood 1996 ; 88 : 2841-51.

5) Bishop JF, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996 ; 87 : 1710-7.

6) Kantarjian H, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010 ; 116 : 4422-9.

7) Lowenberg B, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009 ; 361 : 1235-48.

8) Estey E, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007 ; 109 : 1395-400.

9) Fenaux P, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010 ; 28 : 562-9.

10) Serve H, et al. Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia : Results From a Randomized, Placebo-Controlled Trial. J Clin Oncol 2013 Jul 29. [Epub ahead of print]

P.225 掲載の参考文献

1) Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 ; 89 : 2079-88.

2) Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012 : 120 : 2454-65.

3) Malcovati L, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011 : 96 : 1433-40.

4) Garcia-Manero G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008 ; 22 : 538-43.

5) 黒川峰夫ほか. 不応性貧血 (骨髄異形成症候群) 診療の参照ガイド. 小澤敬也, 編. 特発性造血障害疾患の「診療の参照ガイド」 (平成22年度改訂版). 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 特発性造血障害に関する調査研究班. 2011. pp.57-98.

6) List A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 : 355 : 1456-65.

7) Silverman LR, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome : studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006 ; 24 : 3895-903.

8) Uchida T, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci 2011 : 102 : 1680-6.

9) Cheson BD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006 : 108 : 419-25.

10) Lyons RM, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009 ; 27 : 1850-6.

P.231 掲載の参考文献

1) Garcia-Manero G. Treatment of higher-risk myelodysplastic syndrome. Semin Oncol 2011 ; 38 : 673-81.

2) Damaj G, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes : a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 2012 ; 30 : 4533-40.

3) de Lima M, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome : a dose and schedule finding study. Cancer 2010 ; 116 : 5420-31.

4) Silverman LR, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome : a study of the cancer and leukemia group B. J Clin Oncol 2002 ; 20 : 2429-40.

5) Silverman LR, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome : studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006 ; 24 : 3895-903.

6) Fenaux P, et al. Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol 2009 ; 10 : 223-32.

7) Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes : results of a phase III randomized study. Cancer 2006 ; 106 : 1794-803.

8) Lubbert M, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organisation for Research and Treatment or Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011 ; 29 : 1987-96.

9) Sekeres MA, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012 ; 120 : 4945-51.

10) Natarajan-Ame S, et al. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. Br J Haematol 2012 ; 158 : 232-7.

11) Garcia-Manero G, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012 ; 30 : 2204-10.

12) Sekeres MA, et al. A phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 2011 ; 117 : 1253-61.

13) Chapman CM, et al. ON 01910. Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012 ; 18 : 1979-91.

14) Lowenberg B, et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 2010 ; 28 : 4333-8.

15) Faderi S, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010 ; 28 : 2755-60.

16) Kantarjian H, et al. Phase I clinical and pharmacokinetic study of oral spacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 2010 : 28 : 285-91.

P.241 掲載の参考文献

1) 日本小児血液学会, 編. 小児白血病・リンパ腫の診療ガイドライン. 2011年版. 東京 : 金原出版 ; 2011.

2) Tsukimoto I, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia : The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009 ; 27 : 4007-13.

3) Balgobind BV, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia : results of an international retrospective study. Blood 2009 ; 114 : 2489-96.

4) Imaizumi M, et al ; Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia : the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol 2011 ; 152 : 89-98.

5) Hollink IH, et al, NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011 ; 118 : 3645-56.

6) Kudo K, et al ; Japanese Childhood AML Cooperative Study Group. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia : the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007 ; 25 : 5442-7.

7) Taga T, et al, Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012 ; 120 : 1810-5.

P.249 掲載の参考文献

1) Horibe K, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010) : based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 2013 May 24. [Epub ahead of print]

2) 日本小児血液学会, 編. 小児白血病・リンパ腫の診療ガイドライン. 2011年版. 東京 : 金原出版 ; 2011.

3) Conter V, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia : results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010 ; 115 : 3206-14.

4) Pui CH, et al. Pediatric acute lymphoblastic leukemia : where are we going and how do we get there? Blood 2012 ; 120 : 1165-74.

5) Mattano LA Jr, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia : results from the CCG-1961 randomised cohort trial. Lancet Oncol 2012 ; 13 : 906-15.

6) Pui CH, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 ; 360 : 2730-41.

7) Shultz KR, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia : a children's oncology group study. J Clin Oncol 2009 ; 27 : 5175-81.

8) Eckert C, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001 ; 358 : 1239-41.

Hunger SP, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005 : a report from the children's oncology group. J Clin Oncol 2012 ; 30 : 1663-9.

Roberts KG, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012 ; 22 : 153-66.

P.259 掲載の参考文献

1) Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 ; 355 : 2408-17.

2) Baccarani M, et al. Chronic myeloid leukemia : An Update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009 ; 27 : 6041-51.

3) Marin D, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008 ; 112 : 4437-44.

4) Alvarado Y, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009 ; 115 : 3709-18.

5) Saglio G, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010 ; 362 : 2251-59.

6) Kantarjian H, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010 ; 362 : 2260-70.

7) Mahon FX, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010 ; 11 : 1029-35.

8) Baccarani M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Blood 2013 ; 122 : 872-84.

P.266 掲載の参考文献

1) Baccarani M, et al. Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009 ; 27 : 6041-51.

2) Deininger M, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow-up : sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting abstr) #1126, 2009.

3) Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009 ; 113 : 1619-30.

4) Marin D, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008 ; 112 : 4437-44.

5) Giles FJ, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase : 48-month follow-up results of a phase II study. Leukemia 2013 ; 27 : 107-12.

6) Shah NP, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010 ; 95 : 232-40.

7) Stone RW, et al. Dasatinib Dose-optimization Study in Chronic Phase Chronic Myeloid Leukemia : 3-Year Follow-up with Dasatinib 100mg Once Daily and Landmark Analysis of Cytogenetic Response and Progression-free Survival. J Clin Oncol (JCO Annual Meeting abstr) #7007, 2009.

8) C ortes JE, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011 ; 118 : 4567-76.

9) Marin D, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010 ; 28 : 2381-8.

10) Cortes JE, et al. Change in chronic low-grade nonhematologic adverse events and quality of life in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase switched from imatinib to nilotinib. Blood (ASH Annual Meeting abstr) #3782, 2012.

P.272 掲載の参考文献

1) Hehlmann R. How I treat CML blast crisis. Blood 2012 ; 120 : 737-47.

2) Perrotti D, et al. Chronic myeloid leukemia : mechanisms of blastic transformation. J Clin Invest 2010 ; 120 : 2254-64.

3) Jamieson CH, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004 ; 351 : 657-67.

P.279 掲載の参考文献

1) Eichhorst B, et al ; ESMO Guidelines Working Group. Chronic lymphocytic leukaemia : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 ; 21 Suppl 5 : v162-4.

2) Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011 ; 29 : 544-50.

3) Hallek M, al ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 ; 111 : 5446-56. Erratum in : Blood 2008 ; 112 : 5259.

4) Gribben JG. How I treat CLL up front. Blood 2010 ; 115 : 187-97.

5) Hallek M, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised, open-label, phase 3 trial. Lancet 2010 ; 376 : 1164-74.

6) Eichhorst BF, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009 ; 114 : 3382-91.

7) Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012 ; 120 : 4684-91.

P.285 掲載の参考文献

1) Tam CS, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009 ; 27 : 5587-93.

2) Ballen KK, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010 ; 16 : 358-67.

3) Shimoda K, et al. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia : retrospective analysis of 39 patients in Japan. Int J Hematol 2007 ; 85 : 338-43.

4) Mesa RA, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003 ; 101 : 2534-41.

5) Tefferi A, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 ; 108 : 1158-64.

6) Quintas-Cardama A, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009 ; 27 : 4760-6.

7) Begna KH, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012 ; 87 : 66-8.

8) Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012 ; 366 : 799-807.

9) Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012 ; 366 : 787-98.

10) Cervantes F, et al. Long-term efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Atlanta, GA ; 54th ASH Annual Meeting and Exposition : 2012.

P.289 掲載の参考文献

1) Cervantes F. Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2011 ; 2011 : 215-21.

2) Cortelazzo S, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995 ; 332 : 1132-6.

3) Barbui T, et al. Philadelphia-negative classical myeloproliferative neoplasms : critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011 ; 29 : 761-70.

4) Maugeri N, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders : a new effect for an old drug? J Thromb Haemost 2006 ; 4 : 2593-8.

5) Panova-Noeva M, et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 2011 ; 118 : 2599-601.

6) Carobbio A, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia : an international study of 891 patients. Blood 2011 ; 117 : 5857-9.

7) Harrison CN, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005 ; 353 : 33-45.

8) Gisslinger H, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia : the ANAHYDRET Study, a randomized controlled trial. Blood 2013 ; 121 : 1720-8.

9) Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012 ; 366 : 799-807.

10) Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012 ; 366 : 787-98.

11) Quintas-Cardama A, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008 ; 22 : 965-70.

P.294 掲載の参考文献

1) Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2 : Dameshek's 54 year old speculation comes of age. Best Pract Res Clin Haematol 2007 ; 20 : 5-12.

2) Di Nisio M, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007 ; 136 : 249-59.

3) Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013 ; 368 : 22-33.

4) Passamonti F. How I treat polycythemia vera. Blood 2012 ; 120 : 275-84.

5) Quintas-Cardama A, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009 ; 27 : 5418-24.

6) Kiladjian JJ, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008 ; 112 : 3065-72.

7) Barbui T, et al. Philadelphia-negative classical myeloproliferative neoplasms : critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011 ; 29 : 761-70.

8) Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012 ; 366 : 799-807.

9) Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012 ; 366 : 787-98.

第6章支持療法

P.300 掲載の参考文献

1) 厚生労働省, 編. 血液製剤の使用指針. 改定版. 2005.

血液製剤の使用にあたって. 第4版. 東京 : じほう ; 2009.

P.306 掲載の参考文献

1) 日本輸血・細胞治療学会輸血療法委員会, 編. 輸血副作用対応ガイド. 2011.

2) Janatpour KA, et al. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol 2008 ; 129 : 276-81.

3) 日本赤十字社血液事業本部医薬情報課. 赤十字血液センターに報告された非溶血性輸血副作用. 2011. 輸血情報 2012 ; 1209-134.

4) 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究 (平成20年度). 輸血後鉄過剰症の診療ガイド. 2008.

P.309 掲載の参考文献

1) 日本造血細胞移植学会. 造血細胞移植ガイドライン-移植後早期の感染管理. 第2版. 2012. http://www.jshct.com/guideline/pdf/kansenkanri.pdf.

2) Sehulster L, ChinnRY ; CDC, et al. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003 ; 52 (RR-10) : 1-42.

3) CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. http://www.cdc.gov/mmwr/PDF/rr/rr4910.pdf.

4) CDC. Guidelines for preventing health-care associated pneumonia. 2003. http://www.cdc.gov/hicpac/pdf/guidelines/HApneu2003guidelines.pdf.

5) Passweg JR, et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998 ; 21 : 1231-8.

6) Eckmanns T, et al. The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients : a systematic review. J Infect Dis 2006 ; 193 : 1408-18.

7) CDC. Guidelines for environmental infection control in health-care facilities. 2003. http://www.cdc.gov/hicpac/pdf/guidelines/eic_in_HCF_03.pdf.

8) Tsitsikas DA, et al. Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol 2012 ; 50 : 538-42.

9) CDC. Guideline for isolation precautions : Preventing transmission of infectious agents in healthcare settings. 2007. http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf.

10) 大量調理施設衛生管理マニュアル. 1997. http://www.mhlw.go.jp/topics/bukyoku/iyaku/syoku-anzen/gyousei/dl/130201_9-2.pdf.

P.314 掲載の参考文献

1) Smith TJ, et al. 2006 update of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol 2006 ; 24 : 3187-205.

2) NCCN Clinical Practice Guidelines in Oncology Myeloid growth factors. 2012.

3) Aapro MS, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011 ; 47 : 8-32.

4) Crawford J, et al. Hematopoietic growth factors : ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010 ; 21 Suppl 5 : v248-51.

5) Lyman GH, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor : a systematic review. J Clin Oncol 2010 ; 28 : 2914-24.

6) Freifeld AG, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis 2011 ; 52 : e56-93.

7) Kuderer NM, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy : a systematic review. J Clin Oncol 2007 ; 25 : 3158-67.

8) Clark OA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia : a meta-analysis of randomized controlled trials. J Clin Oncol 2005 ; 23 : 4198-214.

P.318 掲載の参考文献

1) Gafter-Gvili A, et al. Meta-analysis : antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005 ; 142 : 979-95.

2) Schlesinger A, et al. Infection-control interventions for cancer patients after chemotherapy : a systematic review and meta-analysis. Lancet Infect Dis 2009 ; 9 : 97-107.

3) Goodman JL, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992 ; 326 : 845-51.

4) Slavin MA, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995 ; 171 : 1545-52.

5) Kanda Y, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000 ; 89 : 1611-25.

6) Glasmacher A, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies : evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003 ; 21 : 4615-26.

7) Robenshtok E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation : systematic review and meta-analysis. J Clin Oncol 2007 ; 25 : 5471-89.

P.324 掲載の参考文献

1) Paul M, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia : systematic review and meta-analysis. BMJ 2003 ; 326 : 1111.

2) Furno P, et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients : a meta-analysis. Lancet Infect Dis 2002 ; 2 : 231-42.

3) Freifeld AG, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis 2011 ; 52 : e56-93.

4) Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996 ; 37 ; 209-22.

5) Turgeon AF, et al. Meta-analysis : Intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007 ; 146 : 193-203.

6) 正岡徹ほか. 重症感染症に対する抗菌薬との併用療法における静注用ヒト免疫グロブリンの効果. 日本化学療法学会雑誌 2000 ; 48 : 199-217.

7) De Pauw B, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008 ; 46 : 1813-21.

P.334 掲載の参考文献

1) Menell JS, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999 ; 340 : 994-1004.

2) Coiffier B, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome : an evidence-based review. J Clin Oncol 2008 ; 26 : 2767-78.

3) Cairo MS, Bishop M. Tumour lysis syndrome : new therapeutic strategies and classification. Br J Haematol 2004 ; 127 : 3-11.

4) Cairo MS, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases : an expert TLS panel consensus. Br J Haematol 2010 ; 149 : 578-86.

5) 日本癌治療学会, 編. 制吐薬適正使用ガイドライン. 2010年版. 東京 : 金原出版 ; 2010.

6) Basch E, et al. Antiemetics : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011 ; 29 : 4189-98.

7) Roila F, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting : results of the Perugia consensus conference. Ann Oncol 2010 ; 21 (Supp 5) : v232-43.

書評

書評を投稿する

最近チェックした商品履歴

Loading...